Haleon plc (NYSE:HLN) Shares Sold by Bank of Montreal Can

Bank of Montreal Can decreased its holdings in shares of Haleon plc (NYSE:HLN) by 3.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 717,174 shares of the company’s stock after selling 25,390 shares during the quarter. Bank of Montreal Can’s holdings in Haleon were worth $7,652,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Manning & Napier Advisors LLC bought a new stake in shares of Haleon in the second quarter worth $2,833,000. Chartwell Investment Partners LLC lifted its position in shares of Haleon by 107.8% in the 3rd quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock worth $5,030,000 after buying an additional 246,594 shares during the last quarter. Cetera Advisors LLC boosted its stake in Haleon by 524.3% in the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock valued at $696,000 after acquiring an additional 68,857 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Haleon by 106.3% in the 1st quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its stake in Haleon by 55.6% in the third quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company’s stock valued at $5,087,000 after buying an additional 171,877 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley lifted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, Berenberg Bank initiated coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Trading Up 0.1 %

Shares of Haleon stock opened at $9.67 on Tuesday. The company’s fifty day simple moving average is $9.92 and its 200-day simple moving average is $9.44. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $43.77 billion, a price-to-earnings ratio of 28.41, a PEG ratio of 2.92 and a beta of 0.30.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.